Hartmann, Phillipp
Duan, Yi
Miyamoto, Yukiko
Demir, Münevver
Lang, Sonja
Hasa, Elda
Stern, Patrick
Yamashita, Dennis
Conrad, Mary
Eckmann, Lars
Schnabl, Bernd http://orcid.org/0000-0002-6281-825X
Funding for this research was provided by:
National Institutes of Health (K12 HD85036, R01 AA24726, R01 AA020703, U01 AA026939, research center grants P30 DK120515, P50 AA011999)
Biomedical Laboratory Research and Development, VA Office of Research and Development (BX004594)
Biocodex Microbiota Foundation (Grant)
Axial Biotherapeutics (laboratory service agreement)
Article History
Received: 5 June 2021
Accepted: 20 December 2021
First Online: 24 January 2022
Declarations
:
: Phillipp Hartmann, Yi Duan, Yukiko Miyamoto, Münevver Demir, Sonja Lang, Elda Hasa, and Lars Eckmann have no conflicts of interest to disclose. Bernd Schnabl has been consulting for Ferring Research Institute, Gelesis, HOST Therabiomics, Intercept Pharmaceuticals, Mabwell Therapeutics, Patara Pharmaceuticals and Takeda. Bernd Schnabl’s institution UC San Diego has received grant support from Axial Biotherapeutics, BiomX, CymaBay Therapeutics, NGM Biopharmaceuticals, Prodigy Biotech and Synlogic Operating Company. Bernd Schnabl is founder of Nterica Bio. Patrick Stern and Mary Conrad are employees of Axial Biotherapeutics (Woburn, MA, USA). Dennis Yamashita was an employee of Axial Biotherapeutics (Woburn, MA) and is a current employee of Cambrian Biopharma (Brooklyn, NY, USA).
: All institutional and national guidelines for the care and use of laboratory animals were followed. All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee at UCSD.
: Not applicable.
: Not applicable.